Exploring metabolic interventions for CIN cancer therapy by Hussain, Rashid
i 
 
Exploring metabolic interventions for 




Submitted in total fulfillment of the requirements for the degree of 








Discipline of Genetics 
School of Molecular and Biomedical Science 







Table of Contents 
Thesis summary v 
Declaration vii 
Acknowledgement ix 
List of publications xi 
Abbreviations xiii 
Thesis outline xv 
Chapter 1 Introduction 1 
1.1- Cancer 2 
1.2- Cancer therapy 2 
1.3- Chromosomal instability 5 
1.4- Mechanisms of chromosomal instability 7 
1.5- Causes of chromosomal instability in cancer 9 
1.6- Chromosomal instability as cancer target 13 
1.7- The outcomes of chromosomal instability 15 
1.8- Cancer metabolism 18 
1.9- Energy regulations 20 
1.10- Macromolecular requirements 21 
1.11- Redox maintenance 22 
 








1.13- Targeting metabolism in CIN cells and CIN cancers 24 
1.14- Drosophila: a CIN and tumour model 26 
 
1.15- Key points 27 
1.16- Aims of the study  
Chapter 2 
 
Drosophila as a model for chromosomal instability 29 
Chapter 3 Chromosomal instability causes sensitivity to metabolic stress 47 
Chapter 4 
Phosphoenolpyruvate carboxylase is needed to maintain 
glycolysis driven growth in Drosophila tumours 
89 




Appendix 1  




Figure-A-2a: Effect of sodium oxamate on CIN tumour 







Cancer is one the major diseases with highest mortality rate worldwide. Just in Australia, 
by 2020 the number of cancer patients is expected to cross 150,000. This is a huge human 
loss and economic burden not only on the patients and the families, but also on the 
government. Cancer is the outcome of cell growth anomalies, with a potential for 
metastasis. Cancer treatments are available but drug resistance and relapse of the disease is 
very common. One of the factors which promote drug resistance and relapse is 
chromosomal instability (CIN). CIN is a continuous process of chromosomal reshuffling, 
which leads to genetic heterogeneity in tumours. This may help tumours to evolve against 
different stresses like drug treatments. CIN is a common feature of solid and advanced 
tumours, and has been accepted as one of the hallmarks of cancer. CIN offers a cancer 
specific target because it is not present in normal cells.   
In our lab we have a keen interest in targeting CIN for cancer therapy. For this purpose we 
have developed different CIN models in Drosophila melanogaster. Drosophila offers easy 
and targeted genetic manipulations at any development stage e.g. by RNAi, in vivo studies, 
tissue specific expression, and short with characterized genome. There are Drosophila 
models for several cancers, and CIN models have also been studied in Drosophila. CIN 
models have been developed inducing mitotic defects. In my lab we used mad2, rad21, 
bubR1, and brat inhibition to induce CIN locally in a specific tissue or ubiquitously at 
different stages of animal development. All these CIN candidates show high levels of CIN 
when compared to the normal cells and the uniform data from these candidates support the 
concept of targeting CIN for cancer treatment.  
While screening for phosphatases and kinases to kill CIN cells, we found some interesting 
metabolic candidates which had not previously been described as affecting mitosis, 
including Pas-kinase and phosphofructokinase. This instigated us to start screening other 
metabolic alterations which could specifically kill CIN cells. We found metabolic 
candidates from several important metabolic pathways which when knocked down killed 
only CIN cells. Moreover, we found that these metabolic alterations cause mitochondrial 
hyperactivity, oxidative stress, DNA damage, and lipid peroxidation in the CIN 
background, showing CIN cells are sensitive to redox stress.  
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I extended the metabolic study to CIN tumours and found a gluconeogenic protein, 
PEPCK, to be essential for CIN tumour growth. PEPCK deficiency was characterized by 
a high NADH level, which stopped the tumour growth. Redox stress was also an 
important factor for PEPCK deficient tumour survival, as when redox stress was relieved 
the tumour grew. Our results showed that the glycerol-3-phosphate shuttle was 
responsible for elevated ROS production in PEPCK deficient tumours. High NADH and 
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Chromosomal instability (CIN) has been established as one of the hallmarks of cancer, which is 
prevalent in most of the solid and advanced tumours. CIN enhances genetic heterogeneity in 
cancer cells. This heterogeneity provides selective advantages to cancer cells against the 
drugs and the therapies, which are linked to poor prognosis and relapse of cancer.  Altered 
metabolism is another hallmark of cancer, which is being targeted for cancer therapy. In 
this thesis, I have discussed the therapeutic effect of targeting metabolism in CIN cells and 
CIN tumours. Chapter 1 is my introduction in which I have reviewed cancer, its therapy, 
CIN, its types, mechanisms, causes, and therapeutic targeting of CIN. I also review cancer 
metabolism, its targeting for the treatment, and targeting metabolism in CIN cells. Chapter 
2 is a published review article about Drosophila being a model for CIN. In this article I 
have discussed different CIN models and their limitations, then I described Drosophila as 
a model for CIN studies. I later discussed different Drosophila CIN model systems which 
have been studied to understand CIN and cancer. As Drosophila has been extensively 
studied for CIN and cancer therapy, our lab has focused on targeting CIN cells in 
Drosophila. In an earlier study (Shaukat et al, 2012) it was found metabolic candidates such 
as Pas kinase and phosphofructokinase could be crucial for CIN cell survival. Chapter 3 
is a further screening of metabolic candidates. We found few potential targets from all the 
major metabolic pathways whose knock down can specifically kill CIN cells. It was found, 
mitochondrial activity and oxidative stress was high which induced DNA damage and 
apoptosis in CIN cells targeted by these metabolic alterations. In chapter 4, I discuss the 
application of the selected candidates on CIN tumours. We further explain how one of my 
metabolic candidates stopped the tumour growth. This chapter also discusses the 
mechanism of ROS (reactive oxygen species) production and implications of high NADH 
levels in CIN cells, which was deficient in our earlier studies. Chapter 5 is my discussion 
in which I have collectively discussed my results, the significant of my work, my current 
model, and future directions. In appendix 1 I have presented a published review article on 
the role of JNK in response to oxidative DNA damage. This chapter encompasses activation 
of JNK by ROS, outcomes of JNK in response to ROS. Appendix 2 has figures for SOX 



















Cancer is a disease of abnormal cellular growth and its invasion/metastasis into other 
body systems. It is a disease of complex and multiple aberrations which ultimately 
generate cellular neoplastic capabilities and the death of the organism (Meng et al, 2012). 
Cancer has been a leading cause of death worldwide, nearly 8 million every year. Each 
year nearly 14 million new cancer patients are reported, and it costs $1.16 trillion on 
cancer related medicines and treatments in the world. Australia is one of the worst cancer 
stricken countries. About 30% of deaths in Australia are attributed to cancer, with 4.5 
billion AUS dollars spent annually on cancer treatment and management. Soon, by 2020, 
0.15 million new cancer cases are expected, here in Australia (Cancer Council Australia).  
  
The most important factor related to cancer development is our lifestyle and a whole list 
of environmental related agents, which we deliberately or accidentally are exposed to. 
For lung cancer, 90% of cases are related to tobacco smoke exposure (Biesalski et al, 
1998). Liver and digestive tract cancers are related to high alcohol consumption (Dubey 
and Powell, 2008). Another important factor in cancer development is diet and exercise. 
About 30-35% of cancer deaths are found to involved physically inactive and obese 
people (Kushi et al, 2006). Other important factors include: infections, radiation and 
hormonal dysregulations. Only 10% of cancers are hereditary, including: breast cancer, 
ovarian cancer, and hereditary nonpolyposis colorectal cancer (Roukos 2009; 
Cunningham et al, 2010).  
1.2- Cancer therapy  
Cancer is one of the deadliest diseases across the world. The main problems are unreliable 
and ineffective therapies for the disease. The most prevalent treatments for cancer are 
surgery, radiation and chemotherapy (Caley & Jones, 2012). Early stage solid tumours 
can be removed by surgery but advanced and metastatic tumours cannot be eliminated by 
surgery. To overcome this issue radiation and chemotherapy is being used. However, 
radio- and chemo-therapy for cancer can adversely affect patients, sometimes even 
contribute to their death (Schmidt & Bastians, 2007).  
Cancer cells proliferate and thus undergo mitosis a large number of times. Microtubules 
(MT) are part of the cytoplasmic cytoskeleton which is involved in many cellular 
processes including mitotic spindle formation and chromosomal separation (Howard and 
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Hyman, 2003). MT are targeted in some cancer therapies. The most common MT drugs 
are vinca alkaloids and paclitaxel. Both mitotic poisons bind and inhibit polymerization 
of tubulin (Ivachtchenko et al, 2007; Sudakin & Yen, 2007).  However, MT are very 
important in other cellular functions apart from proliferation. MT are involved in 
intracellular transport, cellular shape and integrity. Targeting MT as a cancer therapy has 
not been very effective, since it produces significant haematological and neural side 
effects in the patients (Goa & Faulds, 1994; Lobert, 1997; Rowinsky, 1997). Cancer has 
also been targeted using inhibitors to other mitosis specific proteins, such as polo kinases 
(PLKs), aurora kinase, centromeric protein E (CENPE) (Jackson et al. 2007; Schmidt and 
Bastians 2007; Hosoya and Miyagawa 2014).  These targets still harbor the disadvantage 
of drug resistance emergence following cancer therapy. Nearly 90% of the patients treated 
with MT drugs develop advanced tumours, despite the fact that the drug hinders their 
growth. Nonetheless, these mitotic drugs are still used in therapy and trials are under way 
to enhance their effectiveness (Harrison et al, 2009). 
Another very common therapy for cancer is using drugs that induce DNA damage. Cancer 
cells are proliferative and are under high demand for new genetic material; using DNA 
damaging drugs can cause fatal damage to these highly proliferative cancer cells. These 
drugs usually trigger the DNA damage checkpoint and spindle assembly checkpoint, 
inducing cell cycle arrest or cell death in cancer cells. Alkylating agents have been used 
as DNA damaging drugs, however, these drugs also damage normal proliferating cells 
and cause permanent damage to their DNA (Hosoya and Miyagawa 2014; Tian et al. 
2015). Every proliferating cell should have a DNA damage response; either to rectify it 
or to eliminate the cell using apoptosis. Cancer cells are a peculiar exception in this case. 
Most cancer cells have a compromised DNA damage response due to mutations in their 
DNA damage response genes (Sturm et al, 2003). The most important of these are p53 
and retinoblastoma (Rb); most cancers have mutated p53 and/or Rb. Such defective DNA 
damage responses lead to genome instability, drug resistance and cancer development 
(Masuda et al, 2003). These mutations make the usage of DNA damaging drugs less 
favourable for cancer treatment (Bouwman & Jonkers, 2012). 
Nearly all cancers can develop drug resistance and adaptation to their microenvironment. 
In addition to the previously discussed factors that can promote drug resistance and 
adaptation, another area of current interest in this group is chromosomal instability (CIN). 
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CIN is a continuous loss or gain of chromosome numbers or their segments. CIN is a 
common feature of nearly all solid tumours (Mertens et al, 1994), and helps cancer cells 
progress to metastasis. The presence of chromosomal instability makes these tumours 
more adaptive to cellular and environmental stresses as well as resistant to multiple drugs, 
making them difficult to target with regular therapies (Gao et al, 2007; Heilig et al, 2009; 
Sotillo et al, 2010). CIN, along with aneuploidy has been studied as a possible therapeutic 
target in cancer cells. Cancer cells can tolerate a high level of CIN and aneuploidy, a 
feature rare in normal cells. Tang et al (2011) identified proteotoxic stress in CIN cells 
and targeted them with some metabolic inhibitors, for example heat shock protein 90 
(Hsp90), and found that inducing AMPK (5'AMP activated protein kinase) can restrict 
aneuploid cell growth. 
Altered metabolism has emerged as a new hallmark of cancer. The Warburg effect is one 
of the most studied metabolic characteristics of cancer cell metabolism, which describes 
cancer cells being glycolytic in aerobic conditions and less dependent upon oxidative 
phosphorylation (OXPHOS) for energy production (Heiden et al, 2009). Targeting 
glycolysis using glycolytic inhibitors like 2-DG (2- deoxyglucose), TEPP-46, FX11 and 
STF-31 (a Glu-1 inhibitor) has shown some promising results in tumour suppression. 
However, recent studies emphasize the importance of OXPHOS for cancer cell existence 
and development, which earlier had been underestimated. High levels of TCA enzymes 
(e.g., succinate dehydrogenase, and fumarate hydratase), mitochondrial glutaminolysis 
and ROS suggest a much more significant role for mitochondria than anticipated. An 
important factor in altered metabolism is its implications for genetic regulation in cancer 
cells. 70% of human cancers have over expressed glycolytic genes (Altenberg and 
Greulich, 2004). Mutated mitochondrial genome, p53 inducible regulation of cytochrome 
c oxidase (COX), higher ROS, and dysregulated HIF are some of the genetic links related 
to altered metabolism in cancer (Tran et al, 2016). These extensive studies suggest the 
possibility of targeting the altered metabolism in tumours. 
Cancer cells are difficult to distinguish from normal cells, so finding a suitable target and 
hitting it in cancer cells has not been very fruitful. Rather, proliferative normal cells are 
prone to be tumourigenic with cancer treatments (Caley & Jones, 2012). Many cancer 




In this thesis, I have explored the possibility of targeting CIN tumours with metabolic 
therapy. I discuss CIN and altered metabolism and their possible implications for tumour 
treatment. I looked for possible links between CIN and altered metabolism. We already 
have reported the selective killing of CIN cells by a metabolic change (Pas-kinase). 
PaskRNAi not only induced apoptosis in CIN cells but also induced more DNA damage, 
high ROS, and more mitochondrial dysfunction (Shaukat et al, 2012). The exact 
mechanism for these CIN specific outcomes was not clear, still it encouraged us to target 
metabolism in CIN cells. For this purpose first we targeted a range of metabolic enzymes 
in CIN cells and then verified the results in CIN tumours. Drosophila melanogaster was 
used a model organism to target metabolism in both CIN cells and CIN tumours. 
1.3- Chromosomal instability  
Chromosomal instability has emerged as one of the hallmarks of cancer. It is a continuous 
process of shuffling and reshuffling of a genome, which helps in tumourigenesis and its 
progression. It can start with just an allelic imbalance or a whole chromosome 
missegregation (Bardi et al, 1997). CIN produces heterogeneity which is the driving fuel 
for tumour evolution and drug resistance as CIN is linked with poor prognosis, metastasis, 
and adaptability to environmental and chemical stresses (Carter et al, 2006; Choi et al, 
2009).  
 
Figure 1.1: Kaplan-Meier survival curve of NSCLC (Non-small cell lung cancer), 
according to CIN status. [Taken from (Nakamura et al, 2003)]  
Figure 1.1 shows survival rate of cancer patients with and without CIN. Patients with CIN 
positive cancer have less survival curve than the patients without CIN. Figure 1.2 
describes CIN is often conflated with aneuploidy but they are different terms, although 
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CIN causes aneuploidy in tumours. CIN involves the constant process of genomic 
rearrangement while aneuploidy can describe a stable phenotype. 
 
Figure 1.2: Karyotype of a typical CIN cancer cell (osteosarcoma cell line), showing 
structural and numerical CIN. [Taken from (Jansson & Medema, 2013)]  
The figure 1.2 is showing two types of CIN, structural and numerical CIN. Structural CIN 
arises due to chromosomal alterations of different regions of chromosomes. These may 
occur due translocations, insertions, deletions and amplifications of DNA (Mitelman et 
al, 1997). Whereas, numerical CIN arises due to gain or loss of whole chromosomes 
(Rajagopalan et al, 2003). These events may lead to over-expression of oncogenes or 
knockout tumour suppressor genes which are linked to tumourigenesis (Thompson & 
Compton, 2011) 
Data from the Mitelman database shows about 86% of solid tumours and 72% of 
hematopoietic cancers have chromosomal aberrations, including segmental and 
numerical. Zasadil et al., (2014) calculated CIN and aneuploidy from this database. They 
calculated, about 44% of solid tumors and 14% of hematopoietic cancer cells were CIN 
positive while the rest of the cancer cells were aneuploid. In colorectal cancer with CIN, 
10-100 times more loss or gain of chromosome segments per generation is observed 
(Maria and Chung, 2010).  
 
Aneuploidy is also related to tumour outcomes but there are several aneuploid diseases 
that do not predispose to cancer, and tissues like some hepatocytes are naturally 
aneuploid. The most common outcomes of aneuploidy are proteotoxic stress and redox 
stress (Jefford and Irminger-Finger, 2006). Proteotoxic stress is caused by the excess of 
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proteins produced by additional chromosomes. This produces protein aggregates in the 
aneuploid cells which compromise chaperones e.g., Hsp90 (Ohashi et al, 2015; 
Oromendia et al, 2012). This stress initiates intricate energetic dysregulation like PI3K 
activation, high glucose uptake, autophagy upregulation, and high ROS which can affect 
cell proliferation (Jin et al, 2014). However, these data still do not show if aneuploidy 
could cause tumours.  
1.4- Mechanisms of Chromosomal instability 
Conventionally, CIN is linked to segregation errors of chromosomes during mitosis 
caused by aberrations in the mitotic spindle assembly checkpoint (SAC), kinetochore 
attachment to microtubules or centrosomal dysfunctions (Gollin, 2005; Thompson et al, 
2010). Errors in DNA repair and recombination can also lead to segmental and allelic 
CIN in proliferative cells (Pino and Chung, 2010). In addition, DNA replication stress 
and the state of cellular metabolism are also reported to be related to CIN (Bristow & 
Hill, 2008; Burrell et al, 2013). All these CIN inducing factors are characterized by 
lagging chromosomes or chromosomal bridges, during anaphase of a mitosis (Thompson 
et al, 2010). These CIN inducing factors are related to the spindle assembly checkpoint 
(SAC) of mitosis which ensures proper chromatid separation. The SAC prevents an early 
onset of anaphase and ensures proper alignment and attachment of chromosomes to the 
spindles (Musacchio, 2007). It senses tension at kinetochores when spindles are pulling 
apart during a metaphase. Any aberration during this tension sensing process can shorten 
or lengthen the metaphase which can lead to apoptosis, if not resolved. This tension 
sensing process is ensured by proper bi-directional alignment of chromosomes on the 
spindle and prevents anaphase until the proper attachment is done. (Li et al, 2010; 
Mukherjee et al, 2011). Any deviation from alignment or the bi-directional model allows 
the SAC pathway to delay metaphase (Chi et al, 2009). Resolving the deviations will 
deactivate the SAC and the mitosis will enter anaphase by the separation of sister 
chromatids (Mitelman et al, 2010). The SAC has two major types of proteins: Core and 
Auxiliary proteins. Core proteins include a Mitotic Checkpoint Complex (MCC) which 
includes Mad2, Bub3 and BubR1 and an Anaphase Promoting Complex/cyclosome 
(APC/C), its co-factor Cdc20 and downstream proteins cyclin B, securin, 26S proteasome 
and separase which finally segregates two sister chromatids (Habermann et al, 2009). 
Auxiliary proteins include Mad1, Bub1, Mps1 and AuroraB (Choi et al, 2009). These 
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proteins amplify SAC activity and accelerate MCC formation. During pro-metaphase the 
proteins, core and auxiliary, concentrate at the kinetochore and help in the proper 
attachment of chromatids to microtubules. SAC activity primarily involves activation of 
the MCC which inhibits the interaction of cdc20 with the APC/C. APC/C without its 
effector Cdc20 is unable to polyubiquitinize cyclin-B and securin (Niikura et al, 2007). 
The presence of cyclin-B and securin keeps an optimum level of CDK1 and inactive 
separases during metaphase. Degradation of cyclin-B and separase will decrease the level 
of CDK1 and activate separases, and anaphase will be activated (Fang et al, 2006). 
Interestingly, both hypo- and hyper-activity of the SAC is tumourigenic. Hypo-activity 
of the SAC will not detect any metaphase abnormality and mitosis will enter anaphase 
without proper chromosomal segregation, while hyper-activation of the SAC will inhibit 
anaphase entry and sister chromatids will not be separated. Both hyper and hypo 





Figure 1.3: Aberrant spindle-chromosome attachments and chromosomal bridges lead 
to chromosomal instability. a) Normal chromatid separation during Anaphase, b) a 
centromere attached to both the spindle poles may cause lagging chromosomes, c) ends 
of separating chromatids are unresolved, resulting in the formation of a chromosomal 
bridge. 
1.5- Causes of Chromosomal instability in Cancer 
CIN is created by mechanisms which reduce the fidelity of mitosis (Shen et al, 1998). 
These mechanisms include defects in chromosome cohesion, spindle assembly 
checkpoint (SAC), centrosome copy number, kinetochore-microtubule attachment 
dynamics and cell-cycle regulation (Macklon et al, 2002). These mitotic infidelities can 
induce either whole chromosome segregation errors (W-CIN) or segmental chromosome 
segregation errors (S-CIN).  
1.5.1- Cohesion Defects 
Sister chromatids are attached together during mitosis. The cohesin protein complex 
participates in this sister chromatid cohesion (Nasmyth, 2011). Any defect in sister 
chromatid cohesion can either delay sister chromatid disjunction or cause a premature 
separation. These two aberrant processes can result in unequal chromatid distribution in 
the daughter cells. This partial or premature cohesion failure may results in numerical 
CIN (Figure 1.3), while a complete failure of the cohesion complex may result in 
tetraploidy in one the daughter cells (Thompson et al., 2010). Mutated cohesion genes 
have been identified in human cancer, and when expressed in yeast these induced CIN. 
These genes include Smc1, Smc3, Scc1, Stag1, Stag2, Stag3 and separase  which are 
involved in cohesion of sister chromatids (Jallepalli et al, 2001; Yu et al, 2003; Wirth et 
al, 2006; Barber et al, 2008; Zhang et al, 2008; Iwaizumi et al, 2009; Mannini & Musio, 
2011; Xu et al, 2011). Furthermore, members of the core cohesion complex (i.e. Scc1 and 
Smc3) and cohesion regulators (i.e. separase) are overexpressed in CIN positive cancers 
(Mannini & Musio, 2011). 
1.5.2- Merotelic attachments. 
Lagging chromosomes are another mechanical reason for CIN development. These 
lagging chromosomes result due to merotelic attachment of chromosomes. During mitosis 
a chromatid can get attached to microtubules of both the spindle poles; ideally each 
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chromatid should be attached to microtubules of its respective spindle pole. These lagging 
chromosomes may stay on the metaphase plate without being separated. An anaphase is 











Figure 1.4: Cohesion defects lead to chromosomal instability; a) normal sister chromatid 
separation b) a pair of sister chromatids erroneously moved to one spindle pole, causing 
aneuploidy c) two pairs of chromosomes wrongly moving towards one spindle pole, 
causing aneuploidy for the respective chromosomes. 
conditions, anaphase is not accomplished and the affected chromosomes are left at the 
metaphase plate waiting to be separated apart. These merotelic conditions are 
undetectable by the SAC, because both chromatids have some correct microtubule 
connections which generate some tension which is necessary to keep them on the 
metaphase plate waiting to be separated (see figure 1.4) (Gregan et al, 2011; Holland & 
Cleveland, 2012). To complete a cell cycle these abnormalities may end abruptly, with a 
chromatid on wrong daughter cell, making daughter cells aneuploid. However, if 
merotelic chromatids remain at the metaphase plate and fail to detach from each other, it 
may end in the formation of a micronucleus (Lampson et al, 2004; Pinsky et al, 2006). 
Two main causes of these merotelic attachments are kinetochore-microtubule attachment 









1.5.2.1- Kinetochore-microtubule attachments 
The kinetochore is a protein complex at the centromere which anchor and attaches 
chromatids to microtubules of a spindle assembly. Attachment of kinetochores to multiple 
spindle poles and a weakened ability of the cell to resolve this problem can potentially 
lead to the merotelic condition. These hyper stable kinetochore-microtubule attachments 
have been a characteristic of CIN cancer cells (Thompson & Compton, 2008; Compton, 
2011). Anything which weakens or hyper stabilizes kinetochore-microtubule attachments 
can trigger CIN. The weakening of kinetochore-microtubule attachments may shorten 
mitotic time to correct the errors and a delay may result in abrupt termination of anaphases 
without proper chromatid segregation or aneuploidy.  The best example comes from 
Mad2 protein. Mad2 is a component of the spindle assembly checkpoint (SAC). 
Unattached kinetochores attract Mad2 to form a mitotic checkpoint complex. Its over 
expression and deficiency can produce merotelic attachments (Tanaka et al, 2001; Sotillo 
et al, 2007; Kato et al, 2011; Kabeche & Compton, 2012). Similarly, BubR1 (Bub1-related 
protein kinase), Aurora kinase B (aurora B) and protein phosphatase 1 (PP1) are involved 
in the regulation of kinetochore-microtubules dynamics (Cimini et al, 2006; Emanuele et 
al, 2008; Liu et al, 2009). 
1.5.2.2 Supernumerary Centrosomes 
Centrosomes are a major organelle in a cell which regulates the cell cycle. Centrosomes 
serve as the main microtubule organising centres (MTOC) which maintain microtubule 
organization and the bipolar symmetry of the cell, during mitosis. Defects in centrosomal 
activity create chromosomal segregation defects, which can lead to aneuploidy and CIN. 
The link between supernumerary centrosomes and tumourigenesis has long been studied, 
since Theodor Boveri in 1914. The most common centrosomal defect in cancers is 
multiple centrosomes. This supernumerary condition can lead to attachments of 
kinetochores to multiple centrosomes.  
Extra centrosomes may extend mitotic timings, not satisfying the SAC, resulting in the 
CIN phenotype.  (Boveri, 1914; Pihan et al, 1998; Lingle et al, 2002; Anderhub et al, 
2012). Interestingly, at anaphase these multiple centrosomes typically cluster in such a 
way that leads to bipolar spindle formation. This increases the chances of merotelic 
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attachments which may cause defects in chromosomal segregation.(Brinkley, 2001; 









Figure 1.5: Multi-polar spindle and merotelic attachments lead to chromosomal 
instability. a) Extra centrosomes that cause multiple attachments of sister chromatids to 
two or more centrosomes may delay mitosis but resolve normally, b) Multiple centrosome 
attachments may cause aneuploidy.  
1.5.4 Telomere dysfunction  
Mitosis is a complicated chain of events. It not only divides cells and segregates 
chromosomes but also protects chromosomes from any damage. Telomeres are 
proteinaceous hexameric repeats which stretch along and protect the chromosome during 
DNA replication. Telomeres themselves are protected by shelterin proteins and telomeric 
encoded RNA (Pino and Chung, 2010). Loss of telomeric protection can lead to 
chromosomal breakage-fusion-bridge (B/F/B) cycles which if continued for many 
generations can lead to gross chromosomal rearrangements (O'Hagan et al, 2002).  These 
chromosomal changes can lead to tumour formation, as is seen in mice with Terc-/- (an 
RNA component of telomerase) which leads to tumour formation (Rudolph et al, 
2001). Colorectal cancer usually shows shortened telomeres (Gertler et al, 2004). B/F/B 
cycles can also lead to larger telomeres in some cases. Metastasis in some colorectal 
tumours, such as Dukes C and D tumours, has been attributed to longer telomeric length 
(Engelhardt et al, 1997).  
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1.5.5 DNA damage response 
DNA is in constant danger of damage during replication, transcription and from non-
cellular factors such as toxins. A strong DNA damage response is required to prevent 
further damage. If compromised, DNA damage response failure can lead to cancers. 
Mutations in ataxia-telangiectasia (ATM ), Seckel (ATR), Li-Fraumeni (TP53), and 
hereditary breast-ovarian cancer (BRCA1 and BRCA2 ) genes are linked to tumour 
development in humans (Khanna and Jackson, 2001).  In vivo studies show a direct link 
between DNA damage response malfunctioning and CIN. Haplo-insufficiency of 
histone H2AX in a p53-deficient background can compromise genomic integrity, whereas 
mutants of ATM and H2AX in mice show chromosomal instability (Bassing et al, 2003; 
Zha et al, 2008).  
1.6- Chromosomal instability as cancer target 
CIN cells are genetically heterogeneous, which may provide a selective advantage to CIN 
tumour cells. The CIN is associated with drug resistance, metastasis and relapse of 
tumours. This makes curing CIN tumours a challenging job. However, it also provides an 
opportunity for CIN specific cancer therapy, because CIN is specific to cancers, and found 
with a high frequency in cancer cells (Swanton et al, 2011).  
CIN can also induce apoptosis in cancer cells. Further exacerbating CIN levels in already 
CIN cancer cells can kill CIN cancer cells (Costa and Lengauer, 2002). The anti-mitotic 
drug paclitaxel may accomplish this task by inhibiting Mps1 and Bub1b in CIN cancer 
cells. This drug increases segregation errors in CIN cancer cells and then induces 
apoptosis in cancer cells with a higher mis-segregation rate (Janssen et al, 2009). Aurora 
B has similarly been used in targeting CIN cancer therapy (Payton et al, 2010; Tsuboi et 
al, 2011). Its deficiency induces more CIN which leads CIN cancer cells to cell death 
(Torres et al, 2007; Weaver & Cleveland, 2007; Birkbak et al, 2011; Pfau & Amon, 2012).  
As discussed previously, in cancer cells CIN may produce genetic heterogeneity. Cancer 
cells can take advantage of this genetic diversity to evolve against drugs to acquire 
resistance. This drug resistance offers better survival to the cancer cells against the drugs 
and makes it difficult to target the cancer (Swanton et al, 2009; Sotillo et al, 2010). CIN 
levels are higher in malignant tumours than in benign ones (Yunis, 1983; Mitelman et al, 
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1997), and cancer cells can tolerate high levels of CIN compared to normal cells 
(Mitelman et al, 1997; Campbell et al, 2010; Janssen & Medema, 2011), so it offers an 
attractive target for a cancer-specific therapy.  
Many approaches for targeting chromosomal instability for the treatment of cancer are 
currently in preclinical stages (Cimini et al, 2006; DeLuca et al, 2006; Bakhoum et al, 
2009; Thompson et al, 2010). These include the manipulation of CIN levels in order to 
get a better prognosis and, to generate sensitivity to current therapies. Alternatively, CIN 
cells can be targeted by altering the mechanisms which cancers use to tolerate high levels 
of CIN or CIN related stresses (Manchando et al, 2012). 
Kinetochores as a regulator of microtubule attachments to chromosome have been 
considered as a potential therapeutic target to modify levels of missegregation in cancer 
(Cimini et al, 2006; Bakhoum et al, 2009; Bakhoum et al, 2009b). Alterations in the 
stability of microtubules also affect the process of segregation. Hyper-stability of 
microtubules results in an increase of the chromosomal missegregation rate (Liu et al, 
2009). In contrast, destabilization of attached microtubules up to a certain extent leads to 
a decrease in chromosomal instability which results in better prognosis (Bakhoum et al, 
2009; Bakhoum et al, 2009b). 
Although induction of CIN could induce apoptosis in cancer cells, it could also promote 
the evolution of drug resistance and relapse. A few studies have been done to manipulate 
CIN levels in tumours for cancer therapy, with other cancer therapies. Telomerase 
inhibition can increase CIN up to moderate levels and increases the efficacy of 
conventional anti-cancer drugs (Dome et al, 2005; Stewenius et al, 2007). CENP-F 
(Centrosome protein-F) deficiency also increases the efficiency of anti-cancer drugs, 
although its deficiency alone causes spleen and lung tumour formation. Similarly, PTEN 
exacerbates the CIN condition in Bub1 deficient mice (Weaver et al, 2007). The SAC 
malfunction increases the CIN rate, increasing tumourigenesis in cancer. Other major 
CIN induction mechanisms involve supernumerary centrosomes, which increase the 
chances of missegregation and thus the CIN rate. Mutations that alter the centrosomal 
duplication or bipolar clustering of extra centrosomes have been used to target cells with 
pre-existing centrosome-related CIN (Rebacz et al, 2007; Kwon et al, 2008; Mazzorana 
et al, 2011; Kawamura et al, 2013; Korzeniewski et al, 2013). 
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These studies support targeting CIN for cancer therapy by manipulation of the CIN levels 
in tumours. However, this strategy has a basic flaw. Although drugs used to induce CIN 
can be pro-apoptotic in severely affected CIN cells, these drugs can be beneficial to non-
CIN cancer cells which are present in a tumour. These non CIN cells can become CIN 
cells over a time period and may adapt to the environment and the drugs, resulting in 
relapse and drug resistance (Gao et al, 2007; Heilig et al, 2009; Sotillo et al, 2010). These 
drugs can also induce missegregation in normal cells, increasing further chances of 
tumourigenesis (Goa & Faulds, 1994; Lobert, 1997; Rowinsky, 1997).  
CIN cancer cells can be studied to identify mechanisms which help them to tolerate high 
levels of CIN. CIN cells have proteotoxic stress, with elevated levels of HSP90 (Chen et 
al, 2012; Donnelly and Storchova, 2015). An inhibitor of HSP90, 17-AAG, suppresses 
tumour growth in colon cancer.  In a study to find targets to kill CIN cells specifically, a 
large number of genetic candidates were selected which when knocked down in CIN cell 
killed them, leaving normal cells intact. The genes identified included centrosomal, JNK 
pathway, DNA damage, Wnt signalling pathway, histone kinases, MAPK, metabolic and 
apoptotic genes (Shaukat et al, 2012). 
CIN is present in most solid and advanced tumours and has the potential to be a 
therapeutic target in cancer cells. Inducing CIN by itself in tumours may increase the 
chances of drug resistance and relapse. If CIN cells are studied for their biochemical and 
genetic changes and these changes are targeted in CIN cells, this may increase the chances 
of cell death in CIN tumours. This would be more accurate and specific than simply 
increasing the CIN systemically. 
1.7- The outcomes of chromosomal instability  
Chromosomal instability has become a hallmark of cancer since the identification of 
aneuploidy in cancer cells (Bakhoum et al, 2012). About 85% of solid tumours, and 90% 
of advanced tumours show the CIN phenotype (Mertens et al, 1994). The accepted 
outcome of CIN is tumourigenesis but the explanation of how cancer is induced by the 
CIN is still under investigation (Giam et al, 2015).   
Experimental evidence shows the involvement of CIN in tumour evolution and 
development. The overexpression of spindle assembly checkpoint proteins like Mad2 
leads to CIN. Both hypo- and hyper-activation of Mad2 are CIN inducing. A mouse with 
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either genotype has shown an increased rate of tumourigenesis (Birkbak et al, 2011). 
Neoplastic tumours developed in mice with Mad2 over-expression (Schvartzman et al, 
2011). A large number of mouse models have been tested for CIN induced 
tumourigenesis, such as Bub1, Bub3, BubR1 and Rad21 (Schliekelman et al, 2009; 
Solomon et al, 2014). Furthermore, in another mouse study, over-expression of hec1 (a 
kinetochore-microtubule stabilizing protein) also induced tumours in lung, liver, and 
pancreas (Diaz-Rodriguez et al, 2008). However, most of the studies were done in 
deletion of tumour suppressor background, e.g., loss of p53, p21. Loss of tumour 
suppressor genes can provide tolerance to aneuploidy in CIN cells (Bakhoum et al, 
2012).These results support the role of CIN in tumourigenesis but the question whether 
CIN initiates a tumour is still open.  
Tumour initiation investigations in human patients with mosaic variegated aneuploidy 
syndrome (MVA),which is related to defects in either BubR1, a SAC protein or Cep57, a 
centrosomal protein, and they show aneuploidy, developmental defects and childhood 
cancer (Hanks et al, 2004; Snape et al, 2011; Garcia-Castillo et al, 2008; Suijkerbuijk et 
al, 2010). Tumourigenesis induced by MVA supports the notion of CIN initiating cancer 
but the high aneuploidy rate and other non-cancerous defects in MVA patients demand 
more explanation than just the involvement of the CIN. Unlike the question about CIN 
initiating cancer, the question about CIN’s role in tumour progression is generally straight 
forward; CIN increases tumour growth rate as along as apoptosis is inhibited (Bakhoum 
et al. 2012). Lung tumours driven by the Kras oncogene did not stop growing when the 
oncogene was inhibited if CIN was being driven by Mad2 overexpression (Thompson et 
al, 2010). 
The fact that CIN is involved in tumourigenesis is being challenged by its anti-
tumourigenic role. CIN kills liver tumours, though this might be due to the fact that liver 
cells are already aneuploid and by adding CIN it killed them (Weaver et al, 2007). This 
makes CIN more tissue specific and suggests it might kill tumours that are already 
moderately or highly aneuploid by increasing the deleterious effects of chromosome 
missegregation (Bakhoum et al, 2012).  
Another important outcome of CIN is drug resistance (Giam and Rancati, 2015). This is 
an important aspect of cancer clinical practices which leads to relapse of the tumour. 
CIN+ and CIN- colorectal cancer cell (CRC) lines have been studied for their drug 
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resistance. CIN+ CRC lines were multi-drug resistant compared to the CIN- CRC lines. 
Similarly CIN+ CRC represented worse progression free survival relative to CIN- CRC 
disease (Lee at al, 2011). In a study to investigate drug resistance in CIN cells it was 
found that NEK2 (a centrosomal protein) over expression is involved in drug resistance. 
NEK2 overexpression enhances CIN and cell proliferation (Zhou et al, 2013).  
Mps1 mutants in a p53 heterozygous background increase metabolic stress response 
proteins. Although the authors did not specifically look into the metabolic profiles, they 
found high transcriptome levels of biosynthetic processes, RNA metabolism, cellular 
metabolic processes and gene regulatory processes (Foijer et al, 2014). CIN can lead to 
unbalanced karyotypes which can affect cellular physiology and the disease status 
(Oromendia et al, 2012). These unbalanced karyotypes can initiate a proteotoxic stress 
response in aneuploid cells because loss or gain of chromosomes may affect protein 
folding, assembly of multiprotein complexes and the proteasome, and hence the protease 
capacity of aneuploid cells (Tyedmers et al, 2010; Houck et al, 2012). It was found that 
aneuploid cells have high activity of Hsp 104 - a chaperone, which was also true for the 
aneuploid cell arising from meiotic or mitotic chromosomal missegregation. Similarly 
some disomic yeast strains were prone to more death when Hsp90 inhibitors were used 
(Oromendia et al, 2012). This extra load of proteotoxic effect requires ATP and this 
demands more efficiency of metabolic processes (Ohashi et al, 2015). A critical factor 
which increases with these metabolic stresses is redox stress (Oromendia et al, 2012). 
Metabolism is one of the hallmarks of cancer (Shaukat et al, 2014). Trisomic mouse 
embryo fibroblasts (MEF) do not show a high degree of change in glucose consumption 
and lactate production but glutamine consumption is high in these CIN cells. Similarly, 
amino acid production increased in all trisomic forms of MEF. (Williams et al, 2008). 
This supports the notion that these CIN cells were depending upon the Krebs cycle for 
their energy and biosynthetic pathways. Contrary to these findings in vertebrate cells, 
carbohydrate metabolic genes were upregulated in aneuploid yeast cells. When glucose 
consumption measured it was also increased for yeast CIN cells (Torres et al, 2007). In 
an attempt to kill CIN cells, Pask and Pfrx were identified as metabolic targets. Loss of 
Pask, a regulator of glucose metabolism, led to elevated mitochondria activity, ROS 
generation and apoptosis in CIN cells (Shaukat et al, 2012).  
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In a study on lung cancer associated fibroblasts (LCAF) it was shown that LCAF were 
under stress for overall metabolites compared to normal cell lines. About 203 metabolites 
were identified and measured using mass spectrophotometry. Peptides and amino acids 
were the factors raised in LCAF while carbohydrate and nucleotides were lower in LCAF 
than the normal cell lines (Chaudhri et al, 2013). This data suggest LCAF might be 
glucose deficient and using glutaminolysis for their metabolism. A similar kind of data 
was developed for colorectal cancer tissue in which there was a difference of metabolites 
between normal and the cancer cells. Nucleotides like adenine were lower in the 
colorectal tumour, primary and metastatic cancer samples.  Amino acid derivatives like 
carnitine were two times higher in the colorectal tissue. Importantly, glutathione levels 
were high in the cancer tissue (Williams et al, 2015), suggesting a need for anti-oxidants. 
CIN cells are under redox stress (Kopes et al, 2015) which instigates proteo-toxicity 
(Oromendia et al, 2012) which further increases ROS production activating various 
metabolic pathways like JNK (Vallerie and Hotamisligil, 2010).  
1.8- Cancer metabolism 
Otto Warburg witnessed a high glycolytic rate with increased lactic acid fermentation in 
cancer cells (Warburg, 1956). This discovery paved the way for metabolic studies in 
cancer cells. Continuous research over a long period of time has shown metabolic 
alterations/rewiring in cancer cells. Although these metabolic alterations are not uniform, 
nonetheless altered metabolism is one of the hallmarks of cancer. These metabolic 
alterations encompass a wide range of cellular biochemistry, however, their main target 
is to maintain energy, biomolecules, and redox balance for the proliferation of cancer 
cells (DeBerardinis and Chandel, 2016).   
Higher metabolic rates are linked to higher likelihood of cancers. Major metabolic 
pathways are depicted in Figure 1.6. According to Peto’s paradox (Caulin and Maley, 
2011) big animals like whales and elephants having lower metabolic rates have a lower 
incidence of cancer, while the mouse, on the other hand, having a higher metabolic rate, 
has a 40% lifetime frequency of cancer despite its short lifespan. The most obvious 
explanation is the occurrence of somatic mutations in oncogenes and tumour suppressor 
genes in response to a more rapid metabolism. Higher ROS levels may be the main source 
of these mutations, as an outcome of higher metabolic rates (Dang, 2012). Beside ROS, 
insulin insensitivity is a normal physiological process which can lead to tumourigenesis, 
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by dysregulating glucose and its associated metabolism (like the PI3K-AKT pathway) 
(Khandekar et al, 2011). In a number of different animal models, lowering metabolic rates 
by restricting caloric intake inhibits tumourigenesis (Hursting et al, 2010). Nevertheless, 
mutations in the genes of some of the metabolic pathways, e.g., PI3K, can make the 
tumour cell resistant to the caloric restriction by the over-activation of the energy pathway 
(Kalaany and Sabatini, 2009). 
Whether or not metabolic changes lead to the initiation of cancer is still an open question, 
but metabolic changes have become one of the hallmarks of cancer. Here, I will be 
discussing different metabolic platforms which cancer cells use for their efficient survival 
and replication. 
 
Figure 1.6: Major pathways of central carbon metabolism and key enzymes commonly 
dysregulated in cancer cells. Important pathways implicated in cancer cell proliferation 
are indicated, including glycolysis, TCA cycle, nucleotide synthesis, anti-oxidant, lipid 
synthesis, glutamine metabolism and beta oxidation. Enzymes known to be dysregulated 
in some cancers are shown in red text. Abbreviations: Aco = Aconitase, KGDH=α -
ketoglutarate dehydrogenase, Aldo = Aldolase, ALT = Alanine transaminase, AST = 
Aspartate transaminase, CS = Citrate synthase, Enol = Enolase, FAS = Fatty acid 
20 
 
synthase, FH = Fumarate hydratase, G6PDH = Glucose-6-phosphate dehydrogenase, 
GAPDH = Glyceraldehyde-3-phosphate dehydrogenase, GDH = Glutamate 
dehydrogenase, Gls = Glutaminase, HK = Hexokinase, IDH = Isocitrate dehydrogenase, 
LDH = Lactate dehydrogenase, MDH = Malate dehydrogenase, ME = Malic enzyme, 
PC = Pyruvate carboxylase, PDH = Pyruvate dehydrogenase, PEPCK = 
Phosphoenolpyruvate carboxykinase, PFK = Phosphofructokinase, PGI = 
Phosphoglucose isomerase, PGK = Phosphoglycerate kinase, PGM = Phosphoglycerate 
mutase, PHGDH = Phosphoglycerate dehydrogenase, PK = Pyruvate kinase, RPI = 
Ribulose phosphate isomerase, SCS = Succinyl-CoA synthetase, SDH = Succinate 
dehydrogenase, TPI = Triose phosphate isomerase.  
1.9- Energy regulations 
Cancer cells are found to be very flexible metabolically. They have developed different 
mechanisms to maintain ATP levels, predominantly fuelled through glycolysis, the TCA 
cycle, and providing oxidative molecules to the electron transport chain (ETC). A large 
number of cancer cells have a high glycolytic rate and produce significant amounts of 
lactate, as observed by Otto Warburg - the Warburg effect. This has led to the hypothesis 
of ATP generation by aerobic glycolysis in cancer cells, instead of oxidative 
phosphorylation (OXPHOS) (DeBerardinis and Chandel, 2016). Substantial evidence 
suggests that the Warburg effect is important for anabolic pathways, not just energy 
production, and the elevated glucose uptake is due to dysregulation of oncogenes and 
tumour suppressor genes, and energy regulatory pathways like PI3K pathway (Pavlova, 
2016; Dang, 2012). Slowing down glycolysis in cancer cells has not been very useful to 
stop tumourigenesis (Joshi, 2015). Other studies in cancer cells reveal utilization of 
OXPHOS for ATP production, and mitochondrial utilization in tumourigenesis 
(Weinberg et al, 2010; Martinez-Reyes et al, 2016). This evidence suggests the 
importance of OXPHOS in glycolytic cancer cells.  
Cancer cells also fuel their mitochondria with fatty acids and amino acids, these nutrients 
supply different substrates to the TCA cycle and ETC (electron transport chain) to 
maintain the energy demands of cancer cells. Fatty acid breakdown produces acetyl-CoA, 
and NADH and FADH2, which are involved in ATP production in mitochondria (Ulrike 
and Joanna, 2016). Furthermore, glutaminolysis through glutamine can fuel the TCA 
cycle to facilitate energy production. Besides glutamine, valine, leucine and isoleucine 
levels are elevated in some cancers. These can help cancer cells with ATP production by 
their conversion to acetyl-CoA (Martinez-Reyes et al, 2016).  
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Interesting metabolic remodelling in cancer cells is done under hypoxic and nutrient 
deprived conditions (Fan, 2013). Tumour cells may also survive in hypoxic condition by 
lowering their ATP demand, thus maintaining their ATP/ADP ratio. If the ratio is still 
difficult to maintain, ADP can activate AMPK (AMP Kinase) through AMP, which 
triggers catabolic processes in tumour cells to generate ATP for survival (Hardie and 
Schaffer, 2016). During nutrient depletion, cancer cells use extracellular nutrients to 
produce glutamine and other amino acids as fuel for their TCA cycle. If the nutrient 
deprivation condition persists, the ATP/ADP ratio can also be maintained by inducing 
autophagy through mTOR deactivation. 
Metabolic studies in cancer suggest diverse metabolic phenotypes. This very fact is 
making it hard to target a specific metabolic dysregulation in cancer therapy (Martinez-
Outschoorn et al, 2016). However, cancer cells for their growth, proliferation, and 
metastasis need higher concentrations of glucose, lactate, pyruvate, acetate, glutamine, 
and fatty acids than the normal cells. These common metabolic features of cancer can be 
targeted to treat cancer (Martinez-Outschoorn et al, 2016). 
1.10- Macromolecule requirements 
While metabolic rewiring for energy generation is the fundamental metabolic alteration 
in cancer cells, cancer cells also need an ample supply of biomolecules for proliferation. 
The biomolecule metabolic alterations are not only used in cell proliferation, but also in 
energy production, DNA repair, angiogenesis, hypoxic response, tumourigenesis and 
autophagy (Galluzzi et al, 2014) In this metabolic biosynthesis, simple nutrients (like 
sugar and amino acids) are taken from the extracellular space and then are converted to 
more complex molecules through the main metabolic pathways like glycolysis, the TCA 
cycle, and pentose phosphate pathway (PPP). These processes are energy dependent and 
are regulated through energy sensing pathways like the PI3K-mTOR pathway 
(DeBerardinis and Chandel, 2016).  
Cancer cells can proliferate rapidly which require higher lipid levels for membrane 
synthesis, and cellular signalling (Yoo et al, 2004). Acetyl-CoA, and NADPH, required 
for fatty acid synthesis are well maintained in cancer cells. High pyruvate levels and 
pentose phosphate pathway activity supports fatty acid synthesis. Glutamine, acetate, and 
leucine can provide the carbon skeleton for acetyl-CoA, in addition to glucose when 
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required (Mullen et al, 2012; Yoo et al, 2004). Fatty acid synthesis is also regulated to 
maintain the fatty acid pool in the cell for faster proliferation. SREBP-1, a transcriptional 
factor, has been found in elevated amounts in cancer cells with a high rate of fatty acid 
synthesis. SREBP-1 has been shown to regulate acetyl-CoA conversion to fatty acids, and 
the conversion of acetate and glutamine to acetyl-CoA (Horton 2002). Fatty acid uptake 
can be increased and its oxidation can be decreased under PI3K signalling. This 
maximizes lipogenesis under high lipid demand in cancer cells (Deberardinis, 2006). 
Nucleotides are required for replication and cellular signalling and their production 
involves various metabolic pathways. Cancer cells have been targeted with nucleoside 
analogs and anti-folate drugs for chemotherapy for a long time, but still very little is 
known about the effect of cancer metabolism on nucleotide biosynthesis (DeBerardinis 
and Chandel, 2016). A major pool of nucleotides comes from the PPP pathway, and a 
high glycolytic flux in cancer cells can increase nucleotide production by increased use 
of the PPP pathway. The TCA cycle also contributes to nucleotide synthesis through 
oxaloacetate, which is converted to nucleotides via aspartate. Cancer cells using the TCA 
cycle for biomolecule production can divert it to nucleotide synthesis, when replication 
is required at a high rate. Apart from these intermediates and pathways, NADPH also 
helps in nucleotide synthesis by regulating the oxidative environment in the cells 
(Stincone et al, 2014).  
1.11- Redox maintenance  
Cancer cells have been associated with high ROS production (Liou and Storz, 2010). 
Although ROS has been considered as a lethal by-product of cellular metabolism, now 
ROS is implicated in the modulation of cellular signalling (such as PI3K and MAP Kinase 
pathways) and transcription factors (such as HIF), whose dysregulation can be helpful for 
tumourigenesis (DeBerardinis and Chandel, 2016). Apart from these effects, ROS can 
also oxidize cysteines in proteins; this can induce the unfolded protein response and put 
a cell under metabolic stress (Finkel, 2012). ROS includes different molecules such as 
superoxide anions (O2
-), hydrogen peroxide (H2O2), or hydroxyl radicals (OH
.). These 
chemicals can induce cellular dysregulation, including cell death. Different anti-oxidant 
systems are present in a cell to cope with elevated ROS levels. NADPH oxidase (NOX), 
superoxide dismutase 1 & 2, peroxiredoxins (PRXs), thioredoxin (TXN), thioredoxin 
reductase (TrxR), glutathione peroxidase (GPXs), catalase (Cat), and glutathione are 
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some of the most important anti-oxidants (Rhee et al, 2012; Murphy, 2012).  These anti-
oxidants ultimately convert ROS to H2O and O2, to detoxify a cell with elevated ROS 
levels. Cancer cells have higher levels of ROS, which not only induces cell damage but 
also anti-oxidant enzymes to avoid cell death. One of the important genetic tools to 
increase anti-oxidants in cancer cells is a nuclear factor (erythroid-derived 2)-related 
factor-2 (NRF2) (Jaramillo and Zhang, 2013). NRF2 once activated can induce higher 
production of GPXs, TXNs, GSH synthesis, and cytosolic NADPH, which can evade cell 
death by suppressing ROS levels (Ye at al, 2014).    
1.12- Metabolic targeting of cancer 
Therapeutic targeting of cancer cells has always been complicated but it is critical for 
effective therapy. Large scale research has been done to systemically target cancer cells, 
which may block some critical metabolic pathways that have been dysregulated in cancer 
cells (Le et al, 2010). These therapies have never been very successful possibly because 
cancer cells have all the normal functional metabolic pathways. Although some may be 
dysregulated, their metabolism is very similar to other body tissues e.g., stem cells or, 
immune cells. Cancers also undergo a high degree of metabolic reprogramming at 
different stages of the cancer development, like drug resistance development, metastasis 
and tumourigenesis (Pearce et al, 2013). These facts make it difficult to target a specific 
metabolic pathway in cancer cells, however, it may be more successful to address multiple 
metabolic targets in cancer cells (Gorrini and Harris, 2013). 
Many studies have targeted glycolysis in cancer cells (DeBerardinis and Chandel, 2016). 
Hexokinase 2 (HK2) is involved in the first step of glycolysis, and its overexpression is 
described in many cancers. When inhibited, cancer models like NSCLC and breast cancer 
tissue showed delayed tumour progression, moreover, systemic inhibition of HK2 did not 
show adverse effects on normal tissues.  The other most obvious glycolytic target has 
been lactate dehydrogenase (LDH), which converts pyruvate to lactate. Higher glycolysis 
tends to generate high lactate levels for either conversion to other metabolites or to be 
secreted out of the cancer cells (Heiden, 2011).Targeting LHD-A in MYC driven 
tumours, NSCLS tumours, and myeloid leukaemia shows either regression of the tumour 
or delayed progression (Xie et al, 2014). Glycolysis is regulated by growth factors and 
the energy sensing mechanisms of the cell, such as the PI3K-AKT, mTOR, and HIF 
pathways. These pathways also affect other cellular processes like autophagy, translation 
24 
 
of specific genes, apoptosis, and ribosomal biogenesis. The effect of targeting metabolism 
on these cellular processes in cancer is still under investigation (Heiden, 2011). 
Mitochondria are the other potential metabolic target for cancer therapy. Although cancer 
cells are supposedly glycolytic, still these cells show an abnormal mitochondrial 
metabolism. Mitochondrial metabolism provides some important metabolites to promote 
macromolecule, ATP, and NADPH synthesis for cancer cell proliferation (Ward and 
Thompson, 2012). Utilization of citrate for lipid biosynthesis and nucleotide production 
makes it essential for the cancer cells to replenish the TCA cycle effectively 
(DeBerardinis and Cheng, 2010). This makes intermediate TCA steps critical for cancer 
proliferation. Intermediates like α-ketoglutarate, succinate and fumarate are often 
elevated in lungs, liver and colon cells (Sullivan et al, 2016). Elevated mitochondrial 
activity makes additional ROS. Cancer cells are known to have elevated ROS levels for 
their proliferation, tumourigenesis and metastatic activities. ROS, being highly reactive 
oxygen species, may activate oncogenes, mutate mitochondrial genome, induce hypoxia, 
and loss of tumour suppressor genes (Sullivan et al, 2013; Sullivan et al, 2014; Porporato 
et al, 2014).  
1.13- Targeting metabolism in CIN cells and CIN cancers 
About 90% of solid tumours and 50% of haematopoietic tumours are CIN positive 
(Mitelman et al, 2012). CIN being a hallmark of cancer is present in 70% of sporadic 
colorectal and 70% of lung cancers (Pino and Chung, 2010; Masuda and Takahashi, 
2002). CIN is known to cause proteotoxic stress and metabolic changes in the cells 
(Oromendia et al, 2012) which has been exploited to target cancer cells (Tang et al, 2011). 
Hepatocarcinomas, which are CIN positive, are dependent upon arginine. Depletion of 
arginine by using pegylated arginine deiminase (ADI) increased the life time of patients 
with hepatocarcinoma. The drug is under phase II for clinical trials (Glazer et al, 2010). 
Metformin is probably one of the most discussed metabolic drugs for cancer. It is a 
diabetic drug and is recommended for ovarian cancer (Kasznichi et al, 2014). In a study 
on advanced pancreatic cancer, patients were treated with metformin. Although results 
with metformin were not statistically significant still some patients survived with 
metformin. Moreover, the tumours were at the latter and advanced stage which may have 
compromised the effect of metformin treatment (Kordes et al, 2015). 
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Mitochondria are metabolically very active and diverse organelles and are involved in the 
TCA cycle, OXPHOS, to provide and metabolic intermediates to a cell (Tzameli, 2012). 
Mitochondria in cancer cells are known for their anabolic precursor production which 
cancer cells can use for their replication and metabolic adaptions. Trials are now under 
investigation to target cancer mitochondria for their cancer specific activities (Zong et al, 
2016). Pardee et al., (2014) used an anti-mitochondrial agent CPI-613 against 
hematologic malignancies. CPI-613 was well tolerated by the patients and some of the 
patients (about 29%) achieved their targeted response.   
In a comprehensive study by Tang et al (2011) to target CIN and aneuploidy, the cells 
were hit with various metabolic drugs. They found that in a combination, an energy stress 
inducer (AICAR), and a protein folding inhibitor (17-AAG) were helpful to limit the 
growth of trisomic yeast cell lines and aneuploid cancer cell lines. However, the effect of 
the drugs was limited, and different for different lines. Trisomic yeast lines were 
significantly affected by the drugs but CIN cancer cell lines such as colorectal cancer 
were moderately affected and lung cancer cells were least affected by the drugs. It was 
found these drugs induced AMPK dependent, and p53 dependent as well as independent 
apoptosis in an aneuploid cell. The mechanism by which these drug induced apoptosis in 
the CIN and euploid cells could be not explained. Moreover, AMPK is both pro- or anti-
tumourigenic (Faubert et al, 2014), and p53 is already deregulated in more 50% of human 
cancer (Surget et al, 2013).   
In my lab we targeted CIN to kill cancer cells, as CIN is found in advanced tumours. CIN 
offers cancer specific target for cancer therapy. Initially we targeted kinases and 
phosphatases because these regulatory enzymes are involved in a lot of cellular processes 
such as, cell growth, survival, proliferation (Hunter, 2000). We found inhibition of Pask 
(Pas domain-containing serine/threonine protein kinase), pfrx (phosphofructokinase) 
killed CIN induced progeny and CIN cell in Drosophila wing-disc epithelial cells 
(Shaukat et al, 2012). It was found that the cell death was caspase dependent with high 
ROS levels, and elevated mitochondrial activity. These metabolic candidates had not 
previously been implicated as a potential therapy for targeting CIN cells. Pask is a 
metabolic nutrient sensor and has no known direct effect on glucose consumption, so it 
was surprising to have a CIN specific effect with Pask.  
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Evidence from the literature and our previous findings in the lab suggested further 
screening of metabolic candidates in CIN cells would be useful in identifying further 
CIN-specific metabolic vulnerabilities. All major metabolic candidates were depleted to 
identify a mechanism which could be described to specifically kill CIN cells. In this thesis 
I will be focusing on targeting metabolism in CIN cells and CIN tumours  
1.14- Drosophila: a CIN and tumour model 
CIN is linked to tumourigenesis and is involved in drug resistance and relapse in cancer 
by increasing the genetic diversity of cancer cells (Bakhoum et al, 2012). About 90% of 
solid tumours are CIN positive (Weaver and Cleveland, 2006). Working on CIN in 
cancers has been difficult because by the time cancer is identified, CIN has already 
induced high genetic heterogeneity which makes it difficult to identify the changes which 
led to CIN (Burrell et al, 2013). For this reason induced-CIN models are employed to 
study CIN phenomena. Quite a range of models is available to study CIN from cell 
cultures, yeast to mouse with their advantages and disadvantages (McGranahan et al, 
2012). Cell lines are easy to work with but their huge genetic diversity (every cell is 
genetically different) makes it difficult to get reproducible results and generalized CIN 
therapy (Roschke et al, 2005; Wallqvist et al, 2005). Yeast is another significant CIN 
model, and important metabolic information relating to aneuploidy has been inferred from 
yeast, like high transcriptional profiles and proteotoxic stress in aneuploid yeast cells 
(Oromendia et al, 2012), but yeast is genetically and physiologically far from humans. 
Even some proteins orthologs are not present in yeast, and yeast does not have cancer. 
The only mammalian animal model is a mouse and is employed in cancer studies due to 
genetic and physiological homologies to humans, but difficult genetic manipulations, 
extra time consumption, and difficulty to replicate human gene functions have made it a 
hard choice for genetic experiments (McGranahan et al, 2012). 
Drosophila has been a genetic model for more than a century. It has been completely 
sequenced and a huge set of genetic and biochemical information is available (Fortini et 
al. 2000; Bier 2005). Drosophila is a fairly simple model with substantial genomic 
similarity to human genome: about 60% of genes are conserved, and 75% of human 
disease-causing genes have Drosophila homologues (Pandey and Nichols, 2011). 
Drosophila has a short life cycle, is cost effective and, easy to rear, as well as being easy 
to manipulate genetically, at any stage of its life cycle. More importantly, tissue and stage 
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specific genetic manipulation are feasible in Drosophila (Shaukat et al, 2012). Cancer 
modelling has long been done in Drosophila and several key pathways involved in a 
cancer like Ras, Hippo, Wnt, and Notch were discovered in the fruit fly (Bier, 2005). 
Drosophila has diverse models for CIN study. Mad2, BubR1, Rad21, polo are some of 
the proteins which have been utilized in Drosophila CIN modelling (Liu et al, 2014). 
Tumour studies in Drosophila have been going on for more than a decade in which 
Drosophila explants are implanted into a host fly to analyse tumours and the molecular 
mechanisms of the disease (Caussinus and Gonzalez, 2005). As I also planned CIN 
tumour studies, I considered Drosophila as my first choice as it would be possible to 
perform tissue specific gene manipulation, induce a tumour, explant a tumour in a host 
fly and then follow it for a time period. 
1.15. Key points 
The key points of the introduction are as follows: 
1. CIN is a hallmark of cancer. 
2. CIN can contribute to acquisition of other hallmarks of cancer  
3. CIN leads to chromosomal rearrangements and aberrations which help cancer cells to 
evolve drug resistance, metastasis, relapse, and poor prognosis.  
5. CIN cancer cells can be metabolically different than normal cells. 
6. Targeting metabolism in CIN cells can have therapeutic significance. 
 
1.16. Aims of the study 
The main object of this project has been to identify metabolic targets in CIN cells, which 
could kill CIN cells specifically. We extended the project to evaluate metabolic targeting 
to CIN cancers. The study was done to understand the mechanisms which could be 
involved in killing CIN cells. 
Aim 1: To screen for metabolic candidates whose knockdown can trigger apoptosis in 
CIN cells in Drosophila. 
Aim 2: To implement CIN specific metabolic targeting in CIN tumours, to assess the 
effects of metabolism on cancer therapy. 
Aim 3: Characterization and identification of the metabolic pathways which kill CIN 
cancer cells. 





















Chromosomal instability (CIN) is a characteristic of most solid tumours, and is involved 
in the loss or gain of whole or fractions of chromosomes. CIN has the potential to initiate 
tumorigenesis and may help in tumour evolution against drugs by generating genetic 
diversity (Geigl et al, 2008). Although CIN is a hallmark of cancer, but it also offers a 
cancer specific therapy. CIN cells can be targeted specifically leaving normal cells intact 
(Shaukat et al, 2012). This targeted study can be done on CIN cells like CIN cancer lines, 
however, limitations such as the different genetic makeup of the individual CIN cells, the 
in vitro environment, and reproducibility of the results restrict cancer therapy studies. 
(Roschke et al, 2005; Roschke and Kirsch, 2010). Contrary to CIN cell lines, models for 
induced CIN are more reliable because they start from a common genetic background.  
In this chapter, I have discussed Drosophila as a model for CIN. Drosophila tumour 
tissues develop CIN quickly over a short span of time (Caussinus and Gonzalez, 2005). 
This provides an opportunity to analyse the effect of CIN not only on the tumour tissue 
but also to compare it to normal tissue which develops CIN. I have described limitations 
of CIN cell lines, and the advantages of using Drosophila in CIN tumour studies. 
Aberrations in mitotic processes, like the spindle assembly checkpoint, cytokinesis, and 
DNA repair which were induced in Drosophila to develop different CIN models are also 
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Otto Warburg coined a term “aerobic glycolysis” for cancers with high glucose 
absorption, that produce lactate in presence of oxygen (Warburg. 1925). Herbert Crabtree 
(1929) further extended the Warburg effect and found variability in fermentation in 
tumours. These two studies opened the field of cancer metabolism, which still to this day 
is a very exciting research field to study cancer. Later studies found different metabolic 
changes in cancer, such as the use of glycolysis and Krebs cycle intermediates for 
biosynthesis, amino acid addictions-e.g., glutamine addiction, increased nitrogen 
demand, elevated oxidative stress, and metabolism driven gene regulation (Pavlova and 
Thompson, 2015; Liou and Storz, 2010). These findings have made altered metabolism 
one of the hallmarks of cancer (Hanahan et al, 2011).  
As altered metabolism is a hallmark of cancer it thus offers a therapeutic target to treat it. 
However, metabolic therapy in cancer treatment is still in a preliminary phase because 
cancer cells also possess other metabolic pathways which are present in normal cells 
(Pearce et al, 2013). Moreover, metabolism is a highly integrated and interlinked process, 
so affecting one pathway is sure to have an effect on other related pathways. These and 
other factors, such as the effect of oncogenes on metabolism, have restricted the 
effectiveness of metabolic treatment of cancer (Vander Meiden 2011). This promotes the 
notion of combination therapy for cancer treatment.       
In this work we tested metabolic treatment of chromosomally instable (CIN) cells. CIN 
is another hallmark of cancer and has the potential to induce tumorigenesis (Hanahan et 
al, 2011). Poor prognosis, metastasis, and relapse are common outcomes of CIN in cancer 
(Choi et al, 2009). About 70-80% of solid tumours like colorectal, and lung cancers, have 
CIN (Zasadil et al 2014; Pino and Chung, 2010; Masuda and Takahashi, 2002). 
In this chapter I will be explaining the effect of metabolic disruption on CIN cells. 
Metabolic candidates from several metabolic pathways (glycolysis, Krebs cycle, 
oxidative phosphorylation, gluconeogenesis, glucose metabolism, and PP pathway), 
were found which could induce apoptosis in CIN cells. These metabolic disruptions did 
not adversely affect normal cells. It was also evident that mitochondria were behaving 
abnormally and oxidative stress was high. Oxidative stress was a major cause of 
apoptosis. We could not fully explain the reasons for the apoptosis of CIN cells with 
metabolic disruption. However, the study proved the beneficial outcomes of metabolic 
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In the previous chapter (Chapter 3) I discussed the metabolic targeting of CIN cells. We 
found metabolic proteins which when down regulated in a CIN background, killed the 
CIN cell and did not affect normal cells. However, we could not explain the ROS 
generation mechanism in CIN cells. Moreover, we were not sure about the effectiveness 
of metabolic treatment on CIN tumours. In this chapter, “PEPCK is needed to maintain 
glycolysis-driven growth in Drosophila tumours”, I have addressed these questions.  
Both, CIN and altered metabolism are hallmarks of cancer (Hanahan et al, 2011). CIN by 
itself can cause proteotoxic stress and metabolic changes which can be targeted to treat 
cancer (Oromendia et al, 2012). CIN cancers have been treated with metabolic 
interventions and studies have been reported in which these metabolic interventions 
restrict the CIN tumour growth (Tang et al, 2011; Glazaer et al, 2010). However, specific 
metabolic signatures which are changed in CIN cancer cells are still under investigation.  
To overcome the issue of CIN specific targeting, my lab conducted screening of 
phosphatases and kinases. Candidates, including metabolic candidates, were found which 
could kill CIN cells specifically. Depletion of Pas-kinase, a glucose regulator, and, 
phosphofructokinase (pfrx), a glycolytic enzyme, were found to give CIN specific cell 
death (Shaukat et al, 2014). 
In this chapter I address the above mentioned question of ROS generation and test the 
effectiveness of metabolic interventions to stop CIN tumour growth. A CIN tumour 
model was developed using brat-RNAi neuroblast tissues. Explants of the tissue were 
transplanted in Drosophila hosts. The growth of the tumours was manipulated by genetic 
and chemical interventions. I found PEPCK was essential for CIN tumour growth. In my 
previous and the current study (Chapters 3 and 4), I concluded that PEPCK is involved in 
glyceroneogenesis, and not gluconeogenesis.  The study also shows the importance of 
NADH, which can stop glycolysis and the tumour growth if not oxidized. It was also 
found that the glycerol-3-phosphate shuttle was involved in ROS production which could 
lead to apoptosis. The study emphasises the benefit of unbiased screening for metabolic 
candidates in CIN tumours. This work explains at least one mechanism by which a 
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In this work, major metabolic pathways were inhibited from inducing apoptosis in CIN 
cells. Glycolysis, gluconeogenesis, TCA cycle, PPP pathway, fatty acid metabolism, and 
oxidoreductase genes were initially screened in a mad2RNAi CIN background. The selected 
metabolic candidates were subsequently used in a CIN tumour model, bratRNAi, to test if 
the candidates were able to suppress CIN tumour growth. mad2 is spindle assembly 
checkpoint protein, and its dysregulation can induce CIN in normal cells (Schvartzman 
et al, 2011), whereas brat regulates neuronal differentiation and neuroblasts self-renewal 
(Lee et al, 2006). I selected brat also because the deregulation of its human ortholog 
TRIM3 leads to malignant gliomas (Boulay et al, 2009), especially glioblastoma (GBM) 
(Chen et al, 2014). Thus the findings for brat tumours may have implications for human 
TRIM3 induced cancers. Deficiency of mad2 can induce CIN up to 24% when compared 
to the wild type brain tissue in Drosophila (Shaukat et al, 2014). mad2 dysregulations are 
also related to human cancers, such as colorectal cancer (Li and Zhang, 2004). However, 
tumorigenic effects of mad2 dysregulations are yet to be determined (Ricke et al, 2008). 
In contrast to mad2 deficiency, knockdown of brat can initiate tumorigenesis in 
Drosophila (Basto et al, 2008). I measured CIN rate in brat deficient tissue, and it was 
high about 20% compared to the wild type (Chapter 4, Figure 1g). brat deficiency with 
high proliferative effects and high CIN level gave me an opportunity to test my selected 
metabolic candidates on the tumour with high CIN rate.       
The results were encouraging, with a wide range of candidates killing CIN cells (Chapter 
3-TableS1). Metabolic candidates like PEPCK, Men, Mdh1, and GPDH were also able to 
restrict CIN tumour growth (Chapter 4- Figure 3a, 3b). All the effective candidate's 
induced mitochondrial hyperactivity, high levels of lipid peroxidation, and DNA damage 
in the CIN cells, while a few candidates affected glycolysis to restrict CIN tumour growth 
(Chapter 4-Figure 3b, 3c, 3d, 3e, S2b). I found metabolic candidates were inducing 
oxidative stress in CIN cells, where they might be activating caspase pathways to induce 
apoptosis (Chapter 3-Figure 1, 4, 6; Chapter 4-Figure 1) 
The most prominent factor was oxidative stress, which already is higher in CIN cells 
(Chapter 3-Table 1), and in cancer cells (Liou and Storz, 2010). When some of the anti-
oxidant enzymes were knocked down in CIN cells, an increase in ROS levels was 
observed, whereas no change in ROS levels was detected when anti-oxidant enzymes 
were knocked down in normal cells. ROS can easily damage active macromolecules, such 
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as DNA, lipid membranes, and affect cellular signalling, inducing apoptosis (Day and 
Suzuki, 2006). Over expression of anti-oxidant enzymes (SOD1, catalase) reduced ROS 
levels and rescued apoptosis in metabolically defective CIN cells. This suggests that CIN 
cells are sensitive to ROS. This finding is in accordance with our previous findings that 
candidates of different pathways like JNK, centrosomal, DNA repair and histone kinases 
increased ROS levels in CIN cells (Shaukat et al, 2012). I further tried to rescue PEPCKKD 
CIN tumours with propyl gallate (an anti-oxidant), which allowed some of the tumours 
to grow. This suggests oxidative damage could be a limiting factor in the growth of these 
tumours. The idea to kill cancer cells by inducing more ROS (or by inhibiting anti-
oxidants) is not new and is currently in trials (Cabello et al, 2007; Fry, 2006). However, 
moderately elevated ROS can contribute to cancer cell proliferation, cancer survival, 
angiogenesis and metastasis, and metabolic alterations (Dong et al, 2016; Trachootham 
et al, 2009; Ramanathan et al, 2005; Attia et al, 2008). All these characteristics are 
hallmarks of cancer which can be instigated by ROS. Nonetheless, inducing ROS in 
cancer cells could have a therapeutic advantage (Trachootham et al, 2009) due to the fact 
that cancer cells are already living with moderate ROS levels, which, when increased, 
may kill cancer cells. 
In the initial screening, a diverse range of cellular metabolic candidates was identified 
that made CIN cells susceptible to cell death (Chapter 3-Table 1). Many of these 
metabolic candidates were related to glucose metabolism, like Fructose 1,6 
bisphosphatase, PASK, Glucose 6 phosphatase, G6PD, Wwox, PEPCK, and Galactose 1-
phosphate uridyltransferase. A few were related to the TCA cycle (Idh and Malic enzyme 
b), or beta-oxidation in peroxisomes and mitochondria (Mtpα, Mfe2 and AcetylCoA 
oxidase at 57D).  
Glucose plays a pivotal role in cellular metabolism. A number of biological factors 
regulate glucose homeostasis: Pas-kinase (PASK), a glucose sensing regulator, is one of 
them (DeMille and Grose, 2013). Pask was a strong hit in the initial metabolic CIN 
screening (Shaukat et al, 2012). Its inhibition in CIN cells promoted apoptosis, when 
compared to Pask inhibition in normal cells though Pask has never previously been 
discussed in relation to cancer metabolism. It was found that limiting Pask induced CIN-
specific apoptosis (Shaukat et al, 2012). Higher expression of Pask has been linked to 
higher glucose and glucagon-like peptide-1 (GLP-1) levels in normal human cells 
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(Hurtado-Carneiro et al, 2013), whereas Pask inhibition inhibits glucose stimulated 
insulin activity (Hao et al, 2007).  Pask knockdown in mice shows elevated mitochondrial 
oxidation in beta-pancreatic cells (Hao et al, 2007) and low lipid storage in hepatocytes 
(Wu et al, 2014). This can help to explain Pask’s role in CIN cells: decreasing Pask levels 
can increase mitochondrial activity, producing more ROS which can induce cell death 
when it exceeds the threshold (Chapter 3-Figure 3, 4).  The molecular targets of PASK in 
glucose metabolism are still poorly understood. It is possible that CIN cells with reduced 
Pask function may sense a glucose shortage and up-regulate mitochondrial oxidization, 
increasing ROS to lethal levels (Demille and Grose, 2013). Pask deficiency can also 
induce lipid metabolic defects, as seen in hepatic tissue (Hao et al, 2007; Wu et al, 2014), 
to induce cell death in CIN cells. Cell death was found to be p53 dependent and positive 
for caspase-3 staining in Pask deficient CIN cells (Shaukat et al, 2012). These findings 
suggest ROS and DNA may have acted through p53 to induce apoptosis. However, the 
reason ROS is generated in Pask deficient CIN cell could not be concluded. The main 
reason was we could not draw any appropriate molecular mechanism which would 
explain ROS generation in Pask deficient CIN cells. This is still an open question. As 
Pask is not a direct regulator of glucose metabolism and it is still confined to nutrient 
sensing (Zhang et al, 2015) we found some other glucose regulators (G6PD, PEPCK) 
which have a better characterized effect on glucose consumption than Pask, and can be 
targeted to more easily study metabolism in CIN cells.  
G6PD is involved in the pentose phosphate (PP) pathway which generates NADPH (an 
anti-oxidant) and ribose 5 phosphate (for nucleotide synthesis) (Stanton, 2012). Multiple 
tumours have elevated levels of G6PD. These include leukemia, gastrointestinal cancer, 
renal cell carcinoma, colon cancer, breast cancer, endometrial cancer, liver cancer and 
prostate cancer (Hu et al, 2013). This indicates that G6PD up-regulation supports tumour 
survival, being an anti-oxidant and cell proliferation regulator. Hu et al. (2013) saw the 
lowest growth rate in G6PD deficient tumours in mice. They also observed down-
regulation of cell cycle proteins (cyclin D1, cyclin E, p53 and S100A4). Similarly, when 
G6PD was targeted using inhibitors (Bay 11-7082 and DMF) in erythrocytes, this 
depleted glutathione (GSH) in erythrocytes and induced eryptosis in the cells 
(Ghashghaeinia et al, 2016). CIN cells already suffer redox and replication stress (Shaukat 
et al, 2012). When CIN cells were targeted for G6PD, apoptosis was evident in 
Drosophila wing discs (Chapter 3-Figure S1c). I further checked G6PD in bratRNAi 
130 
 
induced CIN tumours. Unexpectedly, G6PDRNAi could not stop CIN tumour growth. This 
resembles the results of Hu et al. (2013), in which mutant G6PD slowed down the tumour 
growth but did not completely stop it. In our study, the effect of G6PD deficiency on CIN 
tumour growth was not dramatic.  G6PD inhibition would be predicted to affect ribose 5 
phosphate (nucleotide synthesis) or NADPH (anti-oxidant) production (Hay, 2016). 
However, haemolysis in G6PDH deficient patients supports high oxidative stress being 
more detrimental rather than the nucleotide biosynthesis defects (Frank, 2005). Similarly, 
bratRNAi tumours in passage 1 grew very efficiently despite having higher ROS levels than 
the controls (Chapter 4-Figure 1f). In a study to evaluate the role of G6PDH in tumour 
cell proliferation and apoptosis, G6PDH inhibition despite decreasing cell cycle proteins 
like cyclin E, cyclin D1, and increasing apoptotic factors like Bcl-2 and Bcl-xl, also down-
regulated apoptosis factor Fas (Hu et al, 2013). Moreover, some cancers have already 
down-regulated cyclin E levels (Mazumder et al, 2004) which can reduce the effect of 
G6PDH inhibition. Moreover, inhibition of G6PD can be compensated by non-oxidative 
PPP pathways using fructose 6 phosphates and glyceraldehyde 3 phosphate to produce 
ribose 5 phosphate (Hay, 2016). I also found high glucose consumption in CIN tumours 
(Chapter 4-Figure 3 and S2) which can support the use of the non-oxidative PPP pathway 
in G6PD deficiency. Therefore, I could not establish the role of G6PD depletion in tumour 
suppression in our model despite its well characterized role in tumour progression and 
development (Kuo et al, 2000; Patra and Hay, 2014). The PP pathway may be an effective 
target in cancer therapy if candidates more directly involved in nucleotide synthesis, such 
as transketolase, are targeted, as this will also block the non-oxidative PP pathway.  
JNK was another interesting candidate for targeting CIN cells. In our earlier studies we 
found that chromosomal instable cells required JNK for their survival (Shaukat et al, 
2012; Wong et al, 2014). We found the loss of JNK led to DNA damage, increased ROS, 
mitochondrial hyperactivity and apoptosis (Shaukat et al, 2012; Wong et al, 2014). An 
over-expression of JNK has been reported in various cancers, including, T-cell leukemia, 
acute myeloid leukemia, breast cancer, and tumour growth in different mouse models 
(Bode and Dong, 2007). JNK is a stress response protein which is involved in DNA 
damage repair during pre-mitotic cell cycle phases like G1 and G2, so inhibiting JNK 
reduces the DNA damage response and unrepaired DNA damage can lead to caspase 
dependent apoptosis (Wong et al, 2014). Thus I knocked down JNK to induce apoptosis 
in my CIN tumours in response to DNA damage and ROS as seen in CIN wing discs 
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(Shaukat et al, 2014). Contrary to this, JNKKD CIN explants grew normally compared to 
brat mutant explants (Chapter 4 Figure 2). This suggests a loss of a pro-apoptotic function 
of JNK. JNKKD allowed the survival of more aneuploid cells in the tumour explants and 
yet the tissue grew as explants (Chapter 4 Figure 1). JNK also has a pro-apoptotic role. It 
is involved in both extrinsic and intrinsic apoptotic pathways, targeting TNF-a, TRAIL, 
FAS-2 and L, and mitochondrial initiated apoptosis (Elmore, 2007). It was possible that 
depleting JNK would stop the explant growth by inducing apoptosis but the CIN cells 
losing JNK might alternatively have lost apoptotic signals from DNA damage which 
helped the explant to grow. JNK has both apoptotic and anti-apoptotic role in cells (Wong 
et al, 2015). JNK has three isoforms in the mammal, JNK1, JNK2, and JNK3 (Bode and 
Dong, 2007). In a mammalian study JNK1 inhibition increased p53 levels while JNK2 
decreased p53 levels (Tafolla et al, 2005). Acute activation of JNK can help in cell 
survival while either prolonged activation or severe deficiency can promote cell death 
(Wu et al, 2014). The other factor which may be involved in JNK deficient tumour growth 
could be levels of JNK, as I have mentioned above. I have been using RNAi lines which 
do not completely abolish the expression of a target gene. There could be a possibility of 
just enough levels of JNK protein to start the DNA damage repair response. In a time 
course study, JNK activation of less an hour increased cell survival, whereas a longer 
activation of JNK or a complete loss of JNK induced apoptosis (Ventura et al, 2006; Bode 
and Dong, 2007). My results with JNK deficiency strongly suggest for a study to look 
into to both pro- and anti-apoptotic roles of JNK CIN tumours.  
The most exciting results came from mfe2 and PEPCK, which, when knocked down in 
CIN tumour cells, stopped the growth of the explants (Chapter 4-Figure 2d). mfe2 
(multifunctional enzyme 2) is a peroxisomal beta-oxidation enzyme. It is involved in the 
third step of beta oxidation and converts 3-hydroxytetracosanoyl-CoA to 3-
ketotetracosanoyl-CoA and reduces NAD+ during the reaction (Poirier et al, 2006). 
Inhibiting Mfe2 compromises the cell’s ability to breakdown long chain fatty acids to 
short chain fatty acids, which are then involved in the acetyl-CoA production (Wanders 
et al, 2016).  Fatty acid metabolism is becoming a popular therapeutic target in cancer 
studies (Djefaflia et al, 2016). Well known metabolic and neurological disorders are 
related to fatty acid metabolism defects (Zhou et al, 2016). Fatty acid oxidation provides 
cells with acetyl-CoA, a metabolite which can be used in the TCA cycle for energy 
production, or can be used for the biosynthesis of cellular membranes for cell proliferation 
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(Poirier et al, 2006). We expected beta oxidation and the production of acetyl-CoA to be 
an important factor in the effect of mfe2 deficiency on CIN tumours. Surprisingly, when 
explanted bratRNAI CIN tumours were treated with Etomoxir and Trimetazidine (inhibitors 
of beta-oxidation), I could not find any explant growth restriction. This suggested a novel 
role for peroxisomal beta-oxidation, but exploring this needs further investigation. 
Studying peroxisomes and their metabolites as a whole might help to understand this 
restrictive effect on CIN tumours. Unlike mfe2, PEPCK depletion was consistent with 
PEPCK inhibitors in their ability to stop tumour growth (Chapter 4). Thus, we focused 
our attention on explaining the mechanism by which PEPCK might be affecting CIN 
cells. 
PEPCK is involved in gluconeogenesis in the liver and the kidney (Burgess et al, 2004).  
However, its presence in non-gluconeogenic tissues like epithelial tissue suggests a non-
gluconeogenic role in metabolism (Previs et al, 2009). In addition, cancers like 
neuroendocrine prostate cancer, and uterine carcinoma express higher levels of PEPCK 
despite having high hexokinase activity for glycolysis (CBioPortal).  Similarly, whether 
PEPCK is a rate limiting factor in gluconeogenesis is still under debate. Rognstad (1979) 
found that inhibiting PEPCK with mercaptopicolinic acid stops gluconeogenesis, but later 
studies found a limited effect of PEPCK inhibition on gluconeogenic rate (Groen et al, 
1986; Argaud et al, 1991). Some recent studies found that PEPCK is involved in glucose 
metabolism in the tumour growth and it’s proliferation (Montal et al, 2015; Vincent et al, 
2015; Leithner et al, 2015). The studies showed that PEPCK is involved in glutaminolysis 
in the absence of glucose. It was observed that PEPCK converts oxaloacetate (OAA) to 
phosphoenolpyruvate (PEP) which can support TCA and biosynthetic intermediates for 
tumour growth and survival in glucose limited conditions (Vincent et al, 2015; Leithner 
et, 2015), and when glucose is available, PEPCK enhances glycolysis. Major metabolic 
intermediates like pyruvate, glutamate, citrate, fumarate, phosphoenolpyruvate, and 
malate were decreased with PEPCK deficiency (Montal et al, 2015; Vincent et al, 2015; 
Leithner et al, 2015). However, these studies did not address the glycerogenic role of 
PEPCK. PEPCK is one of the rates limiting steps in glyceroneogenesis (Hanson and 
Reshef, 2003; Bartok et al, 2016). Glyceroneogenesis produces glycerol 3 phosphates 
from sources other than glucose like pyruvate, amino acids, and metabolic intermediates 
such as OAA to generate triacyglycerol (Hanson, 2005). When PEPCK was knocked 
down, Drosophila larvae had lower lipid levels (Chapter 3 Figure S3). Bartok et al., 
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(2016) also found PEPCK inhibition lowered glucose, glycerol and TAG levels in the 
animal which suggests the effect of PEPCK on lipid metabolism. From my results I 
predict that the glyceroneogenic role of PEPCK is an important factor to restrict tumour 
growth by affecting ROS production and manipulating the glycolytic rate by affecting 
levels of cytoplasmic NADH. 
 
Figure 5.1; A proposed model for PEPCK role in CIN cancer cells 
Important results came from my ROS experiments. ROS levels were very high in 
PEPCKKD CIN cells and tumours (Chapter 3-Figure 4; Chapter 4-Figure 1f). ROS is 
expected to be produced in mitochondria due to hyper-mitochondrial activation in 
PEPCKKD CIN cells (Chapter 3 figure 2). Mitochondria can produce ROS using the 
glycerol-3-phosphate (G3P) shuttle (Miwa et al, 2003). The G3P shuttle involves both 
cytoplasmic and mitochondrial Glycerol-3-phosphate dehydrogenases, cGPDH and 
mGPDH respectively (Mracek et al, 2012). mGPDH produces ROS from complex I and 
II by reducing ubiquinone in the mitochondrial oxidative phosphorylation process (Miwa 
et al, 2003).  When I inhibited mGPDH using an inhibitor (metformin) it reduced ROS 
levels in both CIN epithelial cells and CIN tumours (Chapter 4, figure 3e). This was 
consistent with high mGPDH activity producing high ROS. This result also suggests that 
glycerol-3-phosphate is not being heavily used to make more TAG and glycerol. Rather, 
the G3P shuttle is involved in NADH oxidation (Shen et al, 2006). NADH is produced 
during glycolysis, and if not oxidized, NADH can hamper glycolysis because no more 
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NAD+ is available for the process to proceed further (Mracek et al, 2012). Thus G3P 
shuttle works as a sink for NADH oxidation, as well as producing glyceraldehyde-3-
phosphate for glycolysis, and ROS in the mitochondria. When the G3P shuttle was 
targeted in CIN tumours it decreased ROS but the tumours could not grow. This is in 
accordance with the biochemical studies showing that elevated levels of mGPDH are 
required in fast growing undifferentiated tumours (Peron et al, 1974; Karsten et al, 1971; 
Dionisi et al, 1970).  In PEPCKKD CIN tumours, the G3P shuttle might not be expected 
to be highly active, as PEPCK inhibition lowers triacyglycride (TAG) and glycerol levels 
in Drosophila hemolymph (Bartok et al, 2016). In this scenario, data about glycerol 
kinase which converts glycerol to G3P, and GPDH is still miss 
ing and needed to be addressed as high ROS production in PEPCKKD CIN cells through 
G3P shuttle would then be difficult to explain (Chapter 4 Figure 4). However, limiting 
G3P shuttle reduced ROS levels in CIN cells (Chapter 4, Figure 3e). The interesting factor 
could be NADH level which should be high in PEPCKKD but still needs to be measured 
to evaluate the importance of NADH oxidation in PEPCK deficient CIN cells. As limiting 
PEPCK should reduce the conversion of OAA to PEP, so less PEP should be available to 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) to be converted to glyceraldehyde 
phosphate, a precursor of glycerol-3-phosphate (Chapter 3 Figure 4; Miwa et al, 2013). 
This would increase NADH levels and restrict glucose consumption (Chapter 4 figure 4; 
Bartok et al, 2016). This NADH can be cleared by G3P thus producing ROS. When 
PEPCKKD CIN tumours were supplemented with anti-oxidants and agents lowering 
NADH levels, the tumours grew (Chapter 4 figure 3b,c). The G3P shuttle seems to be 
more critical in CIN tumours than the other possible sinks for NADH, such as lactate 
dehydrogenase (LDH) and the aspartate/malate shuttle (Vemuri et al, 2006). Under high 
energy and proliferation demands, more pyruvate is needed for energy or lipid synthesis; 
this may make LDH less likely to be active (Fan et al, 2011). Consistent with this, CIN 
tumours did not stop their growth when treated with sodium oxamate, an LDH inhibitor. 
(Appendix-Figure 1a). I also targeted the aspartate/malate shuttle with amino-oxyacetate 
(AOA) and it too did not stop the CIN tumour growth (Chapter 4 figure 3a), highlighting 
the significance of the glycerol phosphate shuttle in clearing NADH. 
This study is an initial work in our lab to demonstrate the importance of metabolism in 
CIN tumour therapy. I believe, if explored further we might have a better mechanistic 
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understanding of this vast metabolic interactive world in the cell to be able to target 
cancer.   
I was also interested in temporal tumour development characteristics, like the tumour 
growth rate, cell death, ROS levels, CIN rate (Chapter 4 Figure 1d, 1e, 1f, 1g), and 
metastasis (Appendix-Figure 1b). I planned for three successive explants of bratRNAi 
tumour tissue for the same time periods.  Passage 1 tumours were distinctive in having 
the highest CIN rate but the lowest cell death rate. The factor responsible for this could 
be the ROS levels, which were lowest in Passage 1 (when compared to the other passaged 
tissues) (Chapter 4-Figure 1f). I observed higher apoptosis in successive passages with 
increasing oxidative stress (Chapter 4-Figure 1e,f). It is known that CIN cells are already 
facing cellular stress due to their aneuploidy, and if ROS is further elevated, these CIN 
cells can undergo apoptosis (Shaukat et al, 2012). It was possible that the high cell death 
and ROS generation in the progressively passaged explanted tissues could be hazardous 
for the host. A high rate of cell death can induce phagocytosis and inflammatory responses 
in the neighbouring normal tissue, at least in vertebrates (Gregory and Pound, 2011). I 
speculate that there is a similar effect in the explant hosts, because I observed successively 
fewer ovarioles in the passaged hosts. Hosts carrying Passage 3 explants (with the highest 
ROS levels and cell death) had the least number of ovary (Appendix-Figure 1b). Ovariole 
number has already been related to environmental stress in Drosophila (Sisodia et al, 
2012; Wayne et al, 2005). These results support the model that excessive CIN can induce 
cell death via higher ROS levels (Liu et al, 2016). My data did not allow me to address 
whether high CIN could contribute to tumour relapses following therapy, because of the 
low number of passages and the limited time given to each explant (13 days) which limits 
the effect of CIN on tumourigenesis. This issue can be solved by anti-oxidant treatments 
or inhibiting apoptosis in the explanted bratRNAI passages, long enough for the passaged 
explant to grow, and to increase the passage numbers. 
CIN cells are already under stress such as redox and proteotoxic stresses (Tang et al, 
2011; Shaukat et al, 2012). I have tried to target CIN cells by manipulating the metabolism 
of the cells. I have shown that metabolic interventions can exacerbate stress conditions in 
CIN cells to kill them. Metabolic candidates from major metabolic pathways like 
glycolysis, TCA cycle, OXPHS, PP pathway, and gluconeogenesis were able to induce 
apoptosis in CIN cells. I further explored this metabolic screening in CIN tumours. Most 
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of the screened and selected candidates could not stop the tumour growth. Of all the 
candidates, PEPCK was the strongest as it stopped the CIN tumour growth. PEPCK loss 
increased NADH levels in CIN cells and to reduce NADH, the glycerol-3-phosphate 
shuttle produced ROS. These two factors, elevated levels of NADH and ROS, may have 
caused apoptosis and limited the tumour growth.  
Future directions 
With this study there are still some open questions which need to be addressed. 
1- The role of JNK in CIN tumours is still unclear. JNK inhibition increased CIN in 
CIN tumours but could not induce much apoptosis to stop CIN tumour growth. 
CIN induces DNA damage, which should initiate apoptosis a part of JNK’s pro-
apoptotic role. JNK activation upon DNA damage is well known. It is accepted 
that small and acute activation of JNK can be pro-survival while persistent and 
strong activation of JNK can be pro-apoptotic (Picco and Pages, 2013). As JNK 
expression was not fully silenced in my RNAi model it is possible that the low 
level of JNK was functionally anti-apoptotic. Using complete knockout of JNK 
may resolve this issue. Moreover, overexpression of JNK might be helpful to 
look into the details of this phenotype.     
2- The effect of PEPCK on lipid metabolism in CIN tumours needs to be 
investigated. We do not know how PEPCK is affecting lipid metabolism. Is it 
affecting the energy generation capabilities of lipids, structural investment of 
lipids like membrane production, cellular signalling or all of these factors? To 
explore this further, levels of glycerol 3 phosphate and related lipid metabolism 
enzymes like glycerol kinase, acylCoA transferase should be measured. Lipid 
profiling should also be done to investigate what kinds of lipid are dysregulated.  
3- Why is there ROS production in PEPCKKD CIN tumours? Although we suggest 
that the G3P shuttle is involved in ROS production, we do not know the detailed 
effect of the G3P shuttle on ROS generation.. The basic experiment can be 
glycerol -3-phosphate analysis in normal and CIN cells, to see if the shuttle is 
still active in the absence of PEPCK.  
4- Clearance of NADH is the main driving force of the glycerol 3 phosphate 
shuttle. The level of NADH has not been measured in a PEPCK depleted context 
and NADH measurement would provide valuable confirmation of the effect of 
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the shuttle. Similarly measurements of phosphoenolpyruvate (PEP), and 
oxaloacetate (OAA) can also help to draw a conclusion about the inhibitory role 
of NADH in PEPCK deficient CIN cells.  
5- The role of nucleotide synthesis in CIN tumours has not been tested. CIN cells 
need nucleotides for their DNA repair and replication. We still do not know 
what nucleotide synthesis interventions can kill tumours. G6PDH was selected 
because it could affect nucleotide synthesis. Alternatives of G6PDH, such as 
transketolase, can be investigated which are directly involved in nucleotide 
synthesis. This would also help to evaluate the possible role of G6PDH as an 
antioxidant or a nucleotide synthesiser.    
Significance 
Cancer is a leading cause of death worldwide. About 15.5 million people are currently 
diagnosed with cancer in the USA (Miller et al, 2016). Cancer treatment may enhance a 
patient’s life but poor prognosis, drug resistance, relapse, and expensive treatments make 
it difficult to treat the cancer patients. One of the many factors which cause poor 
prognosis, drug resistance, and relapse of the disease is chromosomal instability (CIN). 
CIN may help cancer cells to develop genetic diversity which may provide a selective 
advantage against the drugs to the relapse the disease. However, CIN can also be targeted 
to kill cancer cells. In my lab we have targeted CIN specifically by inhibiting different 
proteins in CIN cells. We found inhibition of certain metabolic proteins resulted in the 
death of CIN cells specifically. I investigated the mechanism involved in the selective 
killing of the CIN cells with metabolic interventions.  I found that CIN cells were sensitive 
to metabolic stress. I further extended my results to CIN tumours and found deficiencies 
of metabolic proteins involved in glycerogenesis could stop the CIN tumour growth. 
However, the exact mechanism by which glycerogenesis disruption could stop the tumour 
growth is still in a preliminary phase. Nonetheless, I found NADH and ROS levels could 
be critical for the CIN cells, for their survival. CIN cells already have high ROS levels, 
so increasing ROS in CIN cells can induce apoptosis in CIN cells while not killing normal 
cells. However, the level of NADH levels in CIN cells needs to be addressed. If NADH 




My aims were to identify metabolic targets in CIN cells, to replicate their capacity to kill 
CIN cells in a tumour background, and to characterize the mechanism which could be 
involved with the selected candidates. My initial work identified metabolic candidates 
related to all aspects of metabolism, including glycolysis, Krebs cycle, electron transport 
chain, gluconeogenesis, redox maintenance, and lipid oxidation. When tested in a tumour 
background, only PEPCK and Mfe2 gave me promising results. I focused my attention 
on PEPCK because of its important role in gluconeogenesis and glycerogenesis. I suggest 
a critical role for PEPCK in regulating the glycerol-3-phosphate shuttle in CIN tumours. 
I found that glycerol 3 phosphate is involved in ROS production in CIN cells. I also found 
that PEPCK and the glycerol 3 phosphate shuttle affect glycolysis by affecting NADH 
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The role of JNK signalling in response 






Cancer cells are characterised by elevated oxidative stress. In cancer cells, there is an 
intricate relationship between oxidative stress and the anti-oxidant response to allow their 
survival (Liou and Storz, 2010). Oxidative stress exceeding a threshold limit can kill a 
cell (Shaukat et al, 2014). This threshold limit is hard to define because every cancer cell 
is genetically different, and metabolic and environmental requirements of the individual 
cells induce a different response to a common stress (Sossa et al, 2012; Reuter et al, 2010). 
Oxidative stress is produced by excessive reactive oxygen species (ROS), which are 
produced during cellular metabolism. Any aberration in cellular metabolism can increase 
ROS levels pushing the cell towards oxidative stress (Barzilai and Yamamoto, 2004).    
Oxidative stress is related to a wide range of diseases, including, Alzheimer, Parkinson, 
inflammatory, cardiovascular, diabetes, ageing and cancer (Sosa et al, 2013). One of the 
most common products of oxidative stress is oxidative DNA damage (Cooke et al, 2003). 
Reactive oxygen species (ROS), interact with DNA to produce modified DNA bases. 
These modifications can result in chromosomal aberrations, such as DNA breaks, over a 
period of time (Maser et al, 1997). To overcome these aberrations, the cell activates 
various repair mechanism, which may include the activation of stress responses (Barzilai 
and Yamamoto, 2004). JNK is one of the many stress response proteins which are 
activated in response to DNA damage (Pearce and Humphrey, 2001).       
JNK can regulate NF-κB, p53, AP-1, H2AX protein to induce a wide variety of cellular 
responses to the stimulus (Picco and Pages, 2013). We have found that JNK is an 
important factor for CIN cells survival. When knocked down in CIN cells, loss of JNK 
induces apoptosis (Shaukat et al, 2014). We also found that JNK is important for DNA 
repair in the G2 phase of mitosis (Wong et al, 2015). 
In this chapter “The role of JNK signalling in response to oxidative DNA damage”, we 
will be discussing the effect of JNK in response to oxidative DNA damage. We have 
described various oxidative stress response which can activate JNK. We have also 
discussed JNK activated responses which can regulate cellular behaviour. These 
responses include DNA repair, autophagy and cell death. This chapter may help us to 
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Figure 2b: Number of ovary in the tumour host fly 
Figure 2a: Effect of SOX on tumour growth 
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